NLS Pharmaceutics AG has announced a new shareholder agreement with Alpha Capital Anstalt. The agreement, dated August 5, 2025, involves the exchange of a warrant held by Alpha Capital Anstalt for 207,913 shares of NLS Pharmaceutics' common shares. In return, the company will issue 100,000 common shares to the holder. This exchange is executed under an exemption from registration pursuant to the Securities Act of 1933. The agreement includes a waiver by the holder of any liquidated damages related to past securities registration obligations. The transaction is set to be completed within one trading day, and the new shares will carry the same rights as the previously held warrant shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.